MX2016009807A - Polipéptidos que administran epítopos de cmh de clase i. - Google Patents

Polipéptidos que administran epítopos de cmh de clase i.

Info

Publication number
MX2016009807A
MX2016009807A MX2016009807A MX2016009807A MX2016009807A MX 2016009807 A MX2016009807 A MX 2016009807A MX 2016009807 A MX2016009807 A MX 2016009807A MX 2016009807 A MX2016009807 A MX 2016009807A MX 2016009807 A MX2016009807 A MX 2016009807A
Authority
MX
Mexico
Prior art keywords
cell
polypeptides
mhc class
present
toxin
Prior art date
Application number
MX2016009807A
Other languages
English (en)
Inventor
Poma Eric
Willert Erin
Original Assignee
Molecular Templates Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Templates Inc filed Critical Molecular Templates Inc
Publication of MX2016009807A publication Critical patent/MX2016009807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02022—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2) rRNA N-glycosylase (3.2.2.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se dirige a polipéptidos que proporcionan epítopos de célula T que proporcionan uno o más epítopos de células T CD8+ a la vía de presentación de CHM de clase I de una célula, incluyendo polipéptidos derivados de toxinas que comprenden epítopos de células T incrustados y son desinmunizados. La presente invención describe moléculas que proporcionan un epítopo de células T CD8+, dirigido a células para el suministro dirigido de citotoxicidad a ciertas células, por ejemplo células infectadas o malignas, para la muerte dirigida de tipos específicos de células y el tratamiento de una variedad de enfermedades, trastornos y condiciones, incluyendo cánceres, trastornos inmunes e infecciones microbianas. La presente infección también proporciona métodos para generar polipéptidos capaces de suministrar uno o más epítopos heterólogos de células T a la vía de presentación de CHM clase I incluyendo polipéptidos que son 1) desinmunizados de células B y/o células T CD4+, 2) comprenden epítopos de células T incrustados y/o 3) comprenden efectores de toxina que retienen las funciones de toxina.
MX2016009807A 2014-01-27 2015-01-26 Polipéptidos que administran epítopos de cmh de clase i. MX2016009807A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461932000P 2014-01-27 2014-01-27
US201462049325P 2014-09-11 2014-09-11
PCT/US2015/012968 WO2015113005A1 (en) 2014-01-27 2015-01-26 Mhc class i epitope delivering polypeptides

Publications (1)

Publication Number Publication Date
MX2016009807A true MX2016009807A (es) 2017-02-28

Family

ID=52469328

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2016009807A MX2016009807A (es) 2014-01-27 2015-01-26 Polipéptidos que administran epítopos de cmh de clase i.
MX2016009809A MX2016009809A (es) 2014-01-27 2015-01-26 Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
MX2022010376A MX2022010376A (es) 2014-01-27 2016-07-27 Polipeptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamiferos.
MX2021005131A MX2021005131A (es) 2014-01-27 2016-07-27 Polipeptidos que administran epitopos de cmh de clase i.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2016009809A MX2016009809A (es) 2014-01-27 2015-01-26 Polipéptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamíferos.
MX2022010376A MX2022010376A (es) 2014-01-27 2016-07-27 Polipeptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamiferos.
MX2021005131A MX2021005131A (es) 2014-01-27 2016-07-27 Polipeptidos que administran epitopos de cmh de clase i.

Country Status (12)

Country Link
US (6) US20160347798A1 (es)
EP (4) EP3099704B1 (es)
JP (8) JP6655017B2 (es)
KR (6) KR20230028808A (es)
CN (4) CN112851769A (es)
AU (8) AU2015209063C1 (es)
CA (2) CA2937395A1 (es)
ES (2) ES2877356T3 (es)
HK (2) HK1226082A1 (es)
IL (8) IL302552A (es)
MX (4) MX2016009807A (es)
WO (2) WO2015113005A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541978B (zh) 2010-09-15 2019-12-13 兰德尔·J·米斯尼 使用细菌毒素衍生的转运序列递送生物活性剂的***和方法
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
ES2800630T3 (es) 2013-03-12 2021-01-04 Molecular Templates Inc Proteínas citotóxicas que comprenden regiones de unión de reconocimiento celular y regiones de la subunidad A de la toxina Shiga para la eliminación selectiva de tipos de células específicas
JP2016516742A (ja) 2013-03-28 2016-06-09 アンヴェクティＩｎｖｅｃｔｙｓ ネコ用がんワクチン
US10138488B2 (en) 2013-03-28 2018-11-27 Invectys Cancer vaccine for dogs
WO2015063117A1 (en) * 2013-10-28 2015-05-07 Invectys A telomerase encoding dna vaccine
CA2927539A1 (en) 2013-10-28 2015-05-07 Invectys Gene electrotransfer into skin cells
EP3099704B1 (en) 2014-01-27 2021-03-17 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
JP6935195B2 (ja) * 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR102598038B1 (ko) 2014-05-07 2023-11-07 어플라이드 몰레큘라 트랜스포트 인크. 생물학적 활성 화물의 경구 전달용 콜릭스 독소-유래 융합 분자
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
KR20240038121A (ko) * 2015-05-30 2024-03-22 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
AU2016331923A1 (en) * 2015-10-02 2018-04-26 Regents Of The University Of Minnesota Deimmunized therapeutic compositions and methods
IL259931B2 (en) * 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
CN109071949B (zh) * 2016-05-09 2021-08-31 信越化学工业株式会社 室温固化性有机聚硅氧烷组合物和涂有所述组合物的固化物的基材
KR102557126B1 (ko) 2016-12-07 2023-07-18 몰레큘러 템플레이츠, 인코퍼레이션. 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자
IL267990B2 (en) 2017-01-25 2024-04-01 Molecular Templates Inc Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
AU2018256887A1 (en) * 2017-04-27 2019-11-07 Immusoft Corporation B cells for in vivo delivery of therapeutic agents and dosages thereof
US11351246B2 (en) 2017-05-09 2022-06-07 Invectys SAS Recombinant measles vaccine expressing hTERT
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
CN111836635A (zh) * 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
MX2019009726A (es) * 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
CN109504683A (zh) * 2018-11-13 2019-03-22 广西壮族自治区水产科学研究院 罗非鱼的半乳糖凝集素-3基因序列及其克隆方法
WO2020154531A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
GB201910605D0 (en) * 2019-07-24 2019-09-04 Immetacyte Ltd Tumour infltracting lymphocyte therapy amd uses thereo
WO2021034727A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CN114423793A (zh) 2019-09-18 2022-04-29 分子模板公司 包含志贺菌毒素a亚基支架的pd-l1结合分子
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
CN113621030B (zh) * 2020-07-14 2023-05-26 上海科技大学 一种诱导蛋白质降解的多肽及其应用
WO2022133092A1 (en) 2020-12-16 2022-06-23 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
CA3213295A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
WO2023172983A1 (en) * 2022-03-08 2023-09-14 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
CA2071969A1 (en) 1989-12-22 1991-06-23 John R. Murphy Hybrid molecules having translocation region and cell-binding region
US5635384A (en) 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5552144A (en) 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
CA2162689C (en) 1993-05-12 2000-07-18 Marc D. Better Immunotoxins comprising gelonin and an antibody
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
JPH11506424A (ja) 1995-03-24 1999-06-08 オフィディアン ファーマシューティカルズ インコーポレーテッド ベロ毒素産生大腸菌に対する治療
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
JP2001500730A (ja) 1996-09-10 2001-01-23 ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
CA2222993A1 (en) 1998-02-04 1999-08-04 The Ontario Cancer Institute A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
EP1346731B1 (en) 1998-07-22 2006-12-06 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US20010031485A1 (en) * 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
US7267973B2 (en) * 2000-03-22 2007-09-11 Sibtech, Inc. Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
DE60333004D1 (de) 2002-02-04 2010-07-29 Yoshida Hideo Antikrebsmittel mit verotoxinvarianten
CA2476890C (en) 2002-02-26 2013-07-16 Genencor International, Inc. Subtilisin carlsberg proteins with reduced immunogenicity
CN1649902B (zh) 2002-03-01 2011-04-13 免疫医疗公司 内在化抗-cd74抗体和使用方法
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2003303374A1 (en) 2002-12-20 2004-07-22 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7834258B2 (en) 2003-06-30 2010-11-16 Mu-Hyeon Choe Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
US7585942B2 (en) 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP1727827B1 (en) 2004-03-26 2010-05-12 Molecular Templates, Inc. Library of toxin mutants, and methods of using same
WO2006047517A2 (en) * 2004-10-26 2006-05-04 University Of Maryland Baltimore Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic escherichia coli in cattle
SG10201912554TA (en) 2005-03-23 2020-02-27 Genmab As Antibodies against cd38 for treatment of multiple myeloma
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
FI20055417A0 (fi) 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
EP1919505A2 (en) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
WO2007033497A1 (en) * 2005-09-26 2007-03-29 University Health Network Library from toxin mutants, and methods of using same
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EP1969165A4 (en) 2005-12-23 2010-05-19 Viventia Biotech Inc METHODS FOR GENERATING AND SCREENING HYBRID PROTEIN LIBRARIES, AND USES THEREOF
JP5409014B2 (ja) 2006-02-16 2014-02-05 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 志賀トキソイドキメラタンパク質
US7373982B2 (en) 2006-03-21 2008-05-20 Halliburton Energy Services, Inc. Cements for use across formations containing gas hydrates
CA2673668A1 (en) 2006-12-29 2008-07-10 Osprey Pharmaceuticals Usa, Inc. Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
CN101622352A (zh) * 2006-12-29 2010-01-06 美国奥斯普瑞医药公司 选择和产生修饰的毒素、含有修饰的毒素的缀合物的方法及其应用
GB2456904B8 (en) * 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable neurotensin receptor mutants
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
WO2009017823A2 (en) 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
US20100298238A1 (en) 2007-10-08 2010-11-25 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
EP2048896B1 (en) 2007-10-12 2011-12-21 STMicroelectronics Srl Method and circuit for testing an audio high-frequency loudspeaker being part of a loudspeaker system
CA2705289A1 (en) 2007-11-13 2009-05-22 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
WO2009068630A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
US8315343B2 (en) 2007-12-17 2012-11-20 Telefonaktiebolaget Lm Ericsson (Publ) Multi-antenna receiver interference cancellation method and apparatus
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
CN101629158A (zh) * 2008-07-17 2010-01-20 冯书章 出血性大肠杆菌o157重组疫苗
UA108735C2 (uk) 2008-07-21 2015-06-10 Структурні варіанти антитіл для покращення терапевтичних характеристик
CA2744523A1 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of molecules and displayed molecules and collections
KR101700972B1 (ko) * 2008-10-21 2017-01-31 국제백신연구소 신규한 시겔라 단백질 항원 및 방법
RU2011126896A (ru) 2009-01-23 2013-02-27 Дзе Хенри М. Джексон Фаундейшн Фо Дзе Эдвенсмент Оф Милитэри Медисин, Инк. Композиция и полипептид для стимулирования иммунологической реакции на шига токсин 2 типа
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
US20120258104A1 (en) 2009-07-22 2012-10-11 Cenix Bioscience Gmbh Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
US9174169B2 (en) 2009-08-14 2015-11-03 Unifrax I Llc Mounting mat for exhaust gas treatment device
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2011147986A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2476441A1 (en) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
US20140065172A1 (en) 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
SG191977A1 (en) 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
US8895006B2 (en) * 2011-03-04 2014-11-25 Rutgers, The State University Of New Jersey Ricin ribosome binding protein compositions and methods of use thereof
ES2641877T3 (es) 2011-05-06 2017-11-14 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Inmunotoxina recombinante dirigida a mesotelina
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
WO2013126690A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
JP2014021782A (ja) 2012-07-19 2014-02-03 Canon Inc 画像処理装置、その制御方法及びプログラム
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
ES2800630T3 (es) 2013-03-12 2021-01-04 Molecular Templates Inc Proteínas citotóxicas que comprenden regiones de unión de reconocimiento celular y regiones de la subunidad A de la toxina Shiga para la eliminación selectiva de tipos de células específicas
EP2778173A1 (en) 2013-03-15 2014-09-17 Laboratoire Français du Fractionnement et des Biotechnologies Antibody directed against anthrax toxins and its uses
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
EP3099704B1 (en) 2014-01-27 2021-03-17 Molecular Templates, Inc. Mhc class i epitope delivering polypeptides
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
EP3102245B1 (en) 2014-02-05 2021-09-08 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3872090A1 (en) 2014-03-11 2021-09-01 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
TWI674257B (zh) 2014-03-14 2019-10-11 日商拉夸里亞創藥股份有限公司 作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
CN113332449B (zh) 2014-06-12 2023-12-22 石药集团巨石生物制药有限公司 酶法制备同质的抗体-药物缀合物
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
CN105713087B (zh) 2014-11-12 2020-05-08 北京康乐卫士生物技术股份有限公司 人***瘤病毒58型单克隆抗体及其应用
MX2017010072A (es) 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
DK3265575T3 (da) 2015-03-04 2021-05-31 Igm Biosciences Inc Cd20-bindende molekyler og anvendelser deraf
KR20240038121A (ko) * 2015-05-30 2024-03-22 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자
AU2016297920A1 (en) 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
US11660352B2 (en) 2016-03-29 2023-05-30 Stcube, Inc. Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CA3041078A1 (en) 2016-10-30 2018-05-03 Shanghai Henlius Biotech, Inc. Anti-pd-l1 antibodies and variants
KR102557126B1 (ko) 2016-12-07 2023-07-18 몰레큘러 템플레이츠, 인코퍼레이션. 부위 특이적 접합을 위한 시가 독소 a 서브유닛 작동체 폴리펩타이드, 시가 독소 작동체 스캐폴드, 및 세포-표적화 분자
WO2018124642A2 (ko) 2016-12-26 2018-07-05 단국대학교 천안캠퍼스 산학협력단 치수줄기세포의 상아 모전구세포로의 분화용 조성물 및 상아모전구세포 표면에 특이적으로 결합하는 IgG 또는 IgM 타입 단일 클론 항체
IL267990B2 (en) 2017-01-25 2024-04-01 Molecular Templates Inc Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
JP7201599B2 (ja) 2017-02-28 2023-01-10 中外製薬株式会社 プロテインｌを用いたタンパク質精製
US20200239579A1 (en) 2017-03-09 2020-07-30 Genmab A/S Antibodies against pd-l1
CN111108113B (zh) 2017-09-25 2024-02-23 Jsr株式会社 免疫球蛋白结合蛋白质和使用其的亲和载体
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2020154531A1 (en) * 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
CN114423793A (zh) 2019-09-18 2022-04-29 分子模板公司 包含志贺菌毒素a亚基支架的pd-l1结合分子

Also Published As

Publication number Publication date
AU2020294212A1 (en) 2021-01-28
IL285403B2 (en) 2023-10-01
AU2020294212B2 (en) 2022-08-18
JP6646584B2 (ja) 2020-02-14
US20160340394A1 (en) 2016-11-24
AU2015209065A1 (en) 2016-09-08
CN106103489A (zh) 2016-11-09
AU2019210656B2 (en) 2020-10-22
AU2021200390A1 (en) 2021-03-18
CN111909278B (zh) 2024-04-09
AU2019210656A1 (en) 2019-08-22
IL246632A0 (en) 2016-08-31
JP2023062014A (ja) 2023-05-02
KR20230048153A (ko) 2023-04-10
IL294746B1 (en) 2023-12-01
EP3099704A1 (en) 2016-12-07
IL273035A (en) 2020-04-30
CA2937395A1 (en) 2015-07-30
KR20220011792A (ko) 2022-01-28
MX2021005131A (es) 2021-06-15
AU2019204364C1 (en) 2021-04-15
IL285403B1 (en) 2023-06-01
EP3575312A1 (en) 2019-12-04
IL294746B2 (en) 2024-04-01
AU2015209065C1 (en) 2019-09-26
JP7402556B2 (ja) 2023-12-21
US20210253648A1 (en) 2021-08-19
AU2015209063B2 (en) 2019-05-02
US20220275030A1 (en) 2022-09-01
IL285403A (en) 2021-09-30
IL246632B (en) 2020-03-31
KR20160111951A (ko) 2016-09-27
CN112851769A (zh) 2021-05-28
AU2015209063B9 (en) 2019-08-15
AU2015209065B2 (en) 2019-04-18
AU2022287636B2 (en) 2024-01-04
ES2749862T3 (es) 2020-03-24
CA2937407A1 (en) 2015-07-30
WO2015113007A1 (en) 2015-07-30
JP2021151261A (ja) 2021-09-30
AU2021200390C1 (en) 2023-06-22
EP3099705A1 (en) 2016-12-07
AU2022256081B2 (en) 2023-12-21
IL294746A (en) 2022-09-01
EP3099704B1 (en) 2021-03-17
CN106414483A (zh) 2017-02-15
CN111909278A (zh) 2020-11-10
WO2015113005A1 (en) 2015-07-30
IL287490A (en) 2021-12-01
CN106103489B (zh) 2020-10-02
JP2017509317A (ja) 2017-04-06
IL246701A0 (en) 2016-08-31
JP6655017B2 (ja) 2020-02-26
JP7229570B2 (ja) 2023-02-28
KR20230028808A (ko) 2023-03-02
AU2019210656C1 (en) 2023-06-22
AU2022287636A1 (en) 2023-02-02
US20160347798A1 (en) 2016-12-01
AU2015209063C1 (en) 2020-06-25
AU2019204364B2 (en) 2020-10-22
IL278586B (en) 2021-08-31
EP3868776A1 (en) 2021-08-25
JP2022166140A (ja) 2022-11-01
IL273035B (en) 2021-12-01
AU2015209063A1 (en) 2016-09-08
MX2016009809A (es) 2016-12-02
AU2022256081A1 (en) 2022-11-17
IL287490B (en) 2022-08-01
JP7442879B2 (ja) 2024-03-05
JP2017509318A (ja) 2017-04-06
US20220306701A1 (en) 2022-09-29
US11312751B2 (en) 2022-04-26
HK1226083A1 (zh) 2017-09-22
KR102514910B1 (ko) 2023-03-29
ES2877356T3 (es) 2021-11-16
IL246701B (en) 2020-11-30
AU2021200390B2 (en) 2022-09-15
HK1226082A1 (zh) 2017-09-22
AU2019204364A1 (en) 2019-07-11
EP3099705B1 (en) 2019-06-19
MX2022010376A (es) 2022-09-21
US20190153044A1 (en) 2019-05-23
JP2020073569A (ja) 2020-05-14
IL302552A (en) 2023-07-01
KR20220011790A (ko) 2022-01-28
KR20160113158A (ko) 2016-09-28
KR102500408B1 (ko) 2023-02-16
JP7126729B2 (ja) 2022-08-29
JP2021129598A (ja) 2021-09-09
JP2020079267A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2021005131A (es) Polipeptidos que administran epitopos de cmh de clase i.
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
MX2017006408A (es) Linfocitos t gamma delta modificados geneticamente.
CY1123138T1 (el) Κυτταροτοξικες πρωτεϊνες που περιλαμβανουν περιοχες δεσμευσης στοχευσης-κυtταρων και περιοχες α υπομοναδας τοξινης shiga για επιλεκτικη θανατωση συγκεκριμενων κυτταρικων τυπων
MY189857A (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
MX2018001208A (es) Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
MX2020004420A (es) Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden.
MX2019008840A (es) Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2014165707A3 (en) Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
NZ723879A (en) Glycotargeting therapeutics
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
EP3998341A3 (en) Adenoviral vectors
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
SG10201900933YA (en) Koc1-derived peptide and vaccine including same
AU2018251949A1 (en) Compounds, composition and uses thereof for treating cancer
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
MX2021001357A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
TW201613926A (en) Inhibitors of bruton's tyrosine kinase